undamentalytics Newsletter

Vazzano Joseph Walter: insider trades

Chief financial officer at Abeona Therapeutics Inc. 3 open-market purchases and 7 sales not made under a pre-set plan, reported from November 21, 2022 to September 29, 2026.

Would copying Vazzano Joseph Walter’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. After their sales, the shares moved −23.1% against the index over 12 months on average (a negative figure means selling was the right call); 75% trailed it. None of their purchases could be priced, so there is no copy portfolio.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Vazzano Joseph Walter: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 6 −14.6% −6.8% 83% 2 — — Not enough years
Sales, 12 months after the report 4 −23.1% −26.6% 75% 1 — — Not enough years
Sales, 12 months after the trade 4 −24.5% −25.9% 100% 1 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Abeona Therapeutics Inc. ABEO Chief Financial Officer37November 21, 2022September 29, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
September 29, 2026September 29, 2026 ABEO Sale $47,426 not yetnot yetnot yet
July 9, 2026July 9, 2026 ABEO Sale $173,165 −31.7%not yetnot yet
January 22, 2026January 22, 2026 ABEO Sale $99,490 +0.6%not yetnot yet
October 1, 2025September 29, 2025 ABEO Sale $48,699 −2.6%−21.0%−17.6%
August 15, 2025August 15, 2025 ABEO Sale $110,400 −40.3%−32.2%−34.2%
July 10, 2025July 9, 2025 ABEO Sale $148,908 −9.3%+1.1%−2.6%
June 6, 2025June 6, 2025 ABEO Sale $120,294 −4.3%−40.4%−43.6%
April 26, 2024April 25, 2024 ABEO Purchase $17,609 not yetnot yetnot yet
September 20, 2023September 19, 2023 ABEO Purchase $11,458 not yetnot yetnot yet
November 21, 2022November 18, 2022 ABEO Purchase $10,000 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Vazzano Joseph Walter traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.